Mountain Pacific Venture Fund Invests in SLC Laparoscopic Device Company Xenocor

October 9, 2020

Utah-based Mountain Pacific Venture Fund (MPVF) announced on Monday an investment in Xenocor, a Salt Lake City-based medical device company that has developed the XenoscopeTM, a single-use, multi-purpose HD laparoscope with an integrated light source. Designed to be fog proof, the Xenoscope minimizes common visualization challenges and provides consistent image quality through electrocautery smoke.

MPVF’s investment will support Xenocor’s continued commercialization efforts, with an initial focus on the growing ambulatory surgery center (ASC) market.

“This investment is two scoops of good news,” said Kelvyn Cullimore, president and CEO of BioUtah. “The funding not only recognizes Xenocor’s innovative laparoscopic technology, but it flows from a venture fund right here in our own backyard – something we need more of.” Xenocor has recently joined BioUtah and is one of many examples of Utah’s growing and successful life sciences community.

“Our vision is to make minimally invasive approaches more accessible and affordable to hospitals and patients around the world,” said Evan Kelso, CEO of Xenocor. 

The innovative disposable device improves quality of care by reducing disease transmission and also significantly reduces capital costs.

“We are seeing a steady increase in demand for single-use scopes, driven by a rise in hospital acquired infections and a push from the FDA to start transitioning away from devices that require reprocessing,” said June Chen, MD, Managing Partner of MPVF.

Xenoscope is paired with the Xenobox HD image optimizer, offering universal “plug and play” functionality for seamless integration into any HD monitor. The Xenoscope system is FDA cleared, CE marked and on the market.

MPVF is a Salt Lake City-based venture capital firm focused on supporting emerging early-stage life sciences and biotech companies.